FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS Share Price

Certificat

DE000MG33GZ2

Market Closed - Börse Stuttgart 01:11:24 24/05/2024 am IST
14.33 EUR +0.42% Intraday chart for FAKTOR-OPTIONSSCHEIN - IONIS PHARMACEUTICALS
Current month+31.23%
Date Price Change
23/24/23 14.33 +0.42%
22/24/22 14.27 -3.84%
21/24/21 14.84 +2.06%
20/24/20 14.54 -2.28%
17/24/17 14.88 +14.20%

Delayed Quote Börse Stuttgart

Last update May 24, 2024 at 01:11 am IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying IONIS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MG33GZ
ISINDE000MG33GZ2
Date issued 26/04/2024
Strike 47.5 $
Maturity Unlimited
Parity 0.63 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 15.3
Lowest since issue 8.7
Spread 0.12
Spread %0.85%

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Sector
-
More about the company

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Ionis Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
38 USD
Average target price
57.95 USD
Spread / Average Target
+52.50%
Consensus